Fatal toxic epidermal necrolysis induced by carbamazepine treatment in a patient who previously had carbamazepine-induced Stevens-Johnson syndrome

Journal of the Formosan Medical Association

Volumn 106, Issue 12, 2007, Pages 1032-1037

  Huang, Li Yen ^a   Liao, Wen Chang ^a   Chiou, Chien Chun ^a   Lou, Jenn Ping ^a   Hu, Philip ^b   Ko, Fu Chang ^a  

^a TAOYUAN ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Carbamazepine; Stevens Johnson syndrome; Toxic epidermal necrolysis

Indexed keywords

ANTIBIOTIC AGENT; CARBAMAZEPINE; HYDROCORTISONE;

ADULT; AGITATION; ARTICLE; BODY SURFACE; CASE REPORT; CAUSE OF DEATH; CONJUNCTIVITIS; DEBRIDEMENT; DENIAL; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEVER; GASTROINTESTINAL HEMORRHAGE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; KIDNEY DYSFUNCTION; LUNG EDEMA; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; PSYCHIATRIC DEPARTMENT; RESPIRATORY DISTRESS; SCHIZOPHRENIA; SKIN BIOPSY; SKIN CARE; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

EID: 38049123962     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-6646(08)60079-0     Document Type: Article

References (23)

1. Paquet P, Piérard GE, Quatresooz P. Novel treatment for drug-induced toxic epidermal necrolysis (Lyell's syndrome). Int Arch Allergy Immunol 2005;136:205-16.
2. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333:1600-7.
3. Letko E, Papaliodis DN, Papaliodis GN, et al. Stevens-Johnson syndromes and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol 2005;94:419-36.
4. Paul C, Wolkenestein P, Adle H, et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 1996;134:719-4.
5. Lin MS, Dai YS, Pwu RF, et al. Risk estimates for drugs suspected of being associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study. Intern Med J 2005;35:188-90.
6. Li TH, Chan YC, Sun CC. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis-antecedent drug exposures in 99 hospitalized patients. Dermatol Sinica 1996;14:119-25.
7. Becker DS. Toxic epidermal necrolysis. Lancet 1998;351: 1417-9.
8. Fritsch PO, Sidoroff A. Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Am J Clin Dermatol 2000;1:349-60.
9. McIvor RA, Zaidi J, Peters WJ, et al. Acute and chronic respiratory complications of toxic epidermal necrolysis. J Burn Care Rehabil 1996;17:237-40.
10. Roujeau JC, Chosidow O, Saiag P, et al. Toxic epidermal necrolysis (Lyell syndrome). Am J Dermatol 1990;23: 1039-58.
11. Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998;352:1586-9.
12. Chun WH, Huang SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004: 428:486.
13. Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol 1994;102:28S-30S.
14. Miyauchi H, Hosokawa H, Akaeda T, et al. T-cell subsets in drug-induced toxic epidermal necrolysis. Possible pathogenic mechanism induced by CD8-positive T cells. Arch Dermatol 1991;127:851-5.
15. Garcia DI, LeCleach L, Bocquet H, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drug decrease the risk of death? Arch Dermatol 2000;136:323-7.
16. Yarbrough DR. Experience with toxic epidermal necrolysis treated in a burn center. J Burn Care Rehabil 1996; 17:30-3.
17. Arevalo JM, Lorente JA. Skin coverage with Biobrane biomaterial for the treatment of patients with toxic epidermal necrolysis. J Burn Care Rehabil 1999;20: 406-10.
18. Criton S, Devi K, Sridevi PK, et al. Toxic epidermal necrolysis: a retrospective study. Int J Dermatol 1997;36:923-5.
19. Halebbian PH, Corder VJ, Madden MR, et al. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986;204:503-12.
20. Prins C, Kerdel AF, Padilla RS, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins. Arch Dermatol 2003;139:26-32.
21. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. A prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003;139:33-6.
22. Stahl M, Schifferli JA. The renal risks of high-dose intravenous immunoglobulin treatment. Nephrol Dial Transplant 1998;13:2182-5.
23. Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity of illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149-53.